Switch theme
Sign up to access all valuation multiples
Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.
1949
7.2K+
LTM Revenue $3.3B
LTM EBITDA $784M
$7.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kyowa Kirin has a last 12-month revenue (LTM) of $3.3B and a last 12-month EBITDA of $784M.
In the most recent fiscal year, Kyowa Kirin achieved revenue of $3.4B and an EBITDA of $795M.
Kyowa Kirin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kyowa Kirin valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.3B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $784M | XXX | $795M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $606M | XXX | $630M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 19% | XXX | XXX | XXX |
| Net Profit | $401M | XXX | $411M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kyowa Kirin's stock price is JPY 2354 (or $16).
Kyowa Kirin has current market cap of JPY 1.23T (or $8.5B), and EV of JPY 1.02T (or $7.0B).
See Kyowa Kirin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.0B | $8.5B | XXX | XXX | XXX | XXX | $0.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kyowa Kirin has market cap of $8.5B and EV of $7.0B.
Kyowa Kirin's trades at 2.1x EV/Revenue multiple, and 8.8x EV/EBITDA.
Equity research analysts estimate Kyowa Kirin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kyowa Kirin has a P/E ratio of 21.1x.
See valuation multiples for Kyowa Kirin and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.5B | XXX | $8.5B | XXX | XXX | XXX |
| EV (current) | $7.0B | XXX | $7.0B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 8.9x | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBIT | 11.5x | XXX | 11.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.1x | XXX | 20.6x | XXX | XXX | XXX |
| EV/FCF | -32.2x | XXX | -27.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKyowa Kirin's last 12 month revenue growth is 0%
Kyowa Kirin's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Kyowa Kirin's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kyowa Kirin's rule of X is 22% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kyowa Kirin and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | -5% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 22% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kyowa Kirin acquired XXX companies to date.
Last acquisition by Kyowa Kirin was XXXXXXXX, XXXXX XXXXX XXXXXX . Kyowa Kirin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kyowa Kirin founded? | Kyowa Kirin was founded in 1949. |
| Where is Kyowa Kirin headquartered? | Kyowa Kirin is headquartered in Japan. |
| How many employees does Kyowa Kirin have? | As of today, Kyowa Kirin has 7.2K+ employees. |
| Who is the CEO of Kyowa Kirin? | Kyowa Kirin's CEO is Mr. Masashi Miyamoto. |
| Is Kyowa Kirin publicy listed? | Yes, Kyowa Kirin is a public company listed on TKS. |
| What is the stock symbol of Kyowa Kirin? | Kyowa Kirin trades under 4151 ticker. |
| When did Kyowa Kirin go public? | Kyowa Kirin went public in 1949. |
| Who are competitors of Kyowa Kirin? | Similar companies to Kyowa Kirin include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kyowa Kirin? | Kyowa Kirin's current market cap is $8.5B |
| What is the current revenue of Kyowa Kirin? | Kyowa Kirin's last 12 months revenue is $3.3B. |
| What is the current revenue growth of Kyowa Kirin? | Kyowa Kirin revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Kyowa Kirin? | Current revenue multiple of Kyowa Kirin is 2.1x. |
| Is Kyowa Kirin profitable? | Yes, Kyowa Kirin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kyowa Kirin? | Kyowa Kirin's last 12 months EBITDA is $784M. |
| What is Kyowa Kirin's EBITDA margin? | Kyowa Kirin's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Kyowa Kirin? | Current EBITDA multiple of Kyowa Kirin is 8.9x. |
| What is the current FCF of Kyowa Kirin? | Kyowa Kirin's last 12 months FCF is -$216M. |
| What is Kyowa Kirin's FCF margin? | Kyowa Kirin's last 12 months FCF margin is -6%. |
| What is the current EV/FCF multiple of Kyowa Kirin? | Current FCF multiple of Kyowa Kirin is -32.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
